Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07321332/ritonavir versus placebo in low-risk nonhospitalized adults with symptomatic COVID-19
2021-002857-28Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing PF-07321332 + ritonavir with Placebo (2 arms). Primary endpoint: Time to sustained alleviation of all targeted COVID-19 signs and symptoms. Started Jul 2021; status: completed.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002857-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002857-28.